Japanese approval for CSL Behring's Idelvion in hemophilia B

Biotherapeutics company CSL Behring has received approval in Japan for its hemophilia B treatment Idelvion (coagulation factor IX [recombinant], albumin fusion protein; albutrepenonacog alfa).

The company, which is a subsidiary of Australian biotech CSL Limited (ASX: CSL), has also received approval for the treatment in recent months in the USA, Europe, Canada and elsewhere.

Idelvion can be used for all age groups and the approved treatment regimen includes routine prophylaxis to prevent or reduce the frequency of bleeding episodes, on-demand control and the perioperative management of bleeding.